R&D Boosting clinical trial productivity to prove Eroom wrong According to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least in part, bearing that out.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
